Research Progress of Antibody-Drug Conjugate Therapy for Advanced Gastric Cancer

Gastric cancer is an intractable malignant tumor that has the fifth highest morbidity and the third highest mortality in the world. Even though various treatment options did much to ameliorate the prognosis of advanced gastric cancer, the survival time remained unsatisfactory. It is significant to d...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-05, Vol.12, p.889017-889017
Main Authors: Wang, Na, Mei, Qingyun, Wang, Ziwei, Zhao, Lu, Zhang, Dou, Liao, Dongying, Zuo, Jinhui, Xie, Hongxia, Jia, Yingjie, Kong, Fanming
Format: Article
Language:English
Subjects:
antibody–drug conjugates
drug resistance
gastric cancer
HER2
Oncology
targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer is an intractable malignant tumor that has the fifth highest morbidity and the third highest mortality in the world. Even though various treatment options did much to ameliorate the prognosis of advanced gastric cancer, the survival time remained unsatisfactory. It is significant to develop new therapeutic agents to improve the long-term outcome. Antibody-drug conjugate is an innovative and potent antineoplastic drug composed of a specifically targeted monoclonal antibody, a chemical linker, and a small molecule cytotoxic payload. Powerful therapeutic efficacy and moderate toxicity are its preponderant advantages, which imply the inevitable pharmaceutical developments to meet the demand for individualized precision therapy. Nevertheless, it is unavoidable that there is a phenomenon of drug resistance in this agent. This article systematically reviewed the recent progress of antibody-drug conjugates in advanced gastric cancer therapy.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.889017